This company has been acquired
Cardiovascular Systems (CSII) Stock Overview
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CSII Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Cardiovascular Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.00 |
| 52 Week High | US$20.57 |
| 52 Week Low | US$12.26 |
| Beta | 0.74 |
| 1 Month Change | 0.70% |
| 3 Month Change | 49.48% |
| 1 Year Change | 1.63% |
| 3 Year Change | -52.38% |
| 5 Year Change | -25.90% |
| Change since IPO | 123.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| CSII | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.1% | -1.3% | 0.7% |
| 1Y | 1.6% | -18.6% | 20.6% |
Return vs Industry: CSII exceeded the US Medical Equipment industry which returned -0.1% over the past year.
Return vs Market: CSII exceeded the US Market which returned -5.3% over the past year.
Price Volatility
| CSII volatility | |
|---|---|
| CSII Average Weekly Movement | 14.0% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CSII's share price has been volatile over the past 3 months.
Volatility Over Time: CSII's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 725 | Scott Ward | www.csi360.com |
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions.
Cardiovascular Systems, Inc. Fundamentals Summary
| CSII fundamental statistics | |
|---|---|
| Market cap | US$843.96m |
| Earnings (TTM) | -US$37.87m |
| Revenue (TTM) | US$239.84m |
Is CSII overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSII income statement (TTM) | |
|---|---|
| Revenue | US$239.84m |
| Cost of Revenue | US$66.22m |
| Gross Profit | US$173.63m |
| Other Expenses | US$211.49m |
| Earnings | -US$37.87m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 72.39% |
| Net Profit Margin | -15.79% |
| Debt/Equity Ratio | 0% |
How did CSII perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/27 05:48 |
| End of Day Share Price | 2023/04/27 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cardiovascular Systems, Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |
| Lawrence Neibor | Baird |
| Matthew Miksic | Barclays |